Drugs trials on diabetics exposed as a 'catastrophe for the poor'
Wednesday 13 June 2012
Related articles
Tens of thousands of diabetics in poor countries have been switched to expensive new medications that have no additional clinical benefits as a result of lax international regulations, new research warns.
Post-marketing studies for insulin analogue drugs have left thousands of poor patients in India on treatment which costs eight times the amount of generic drugs which are just as effective. This means some patients are spending a third of their household incomes on medications with catastrophic consequences for their families, according to John Yudkin, emeritus professor of medicine at University College London.
The research comes after an investigation by The Independent last year revealed some devastating consequences of the globalisation of drug trials.
The diabetes patients, who in low and middle income countries generally pay for their own medications, are recruited by doctors paid by the drugs companies for every person they enlist onto the observational study. In developed countries like the UK, France and Germany, the National Health Service or insurance companies foot the bill.
The three papers, published in the British Medical Journal, call for much tighter regulation of post-marketing studies, which they claim are being used by drug companies for predominantly commercial a nd not scientific reasons.
These studies, which are meant to test the drug in real-life settings, are subject to far fewer rules and less rigorous monitoring than the controlled clinical trials. The drug companies deny that observational studies are being used for marketing purposes.
Professor Edwin Gale, emeritus professor of diabetic medicine at the University of Bristol, who analysed the post-marketing studies of insulin analogues carried out by three drug companies involving 400,000 diabetics worldwide, said there was little evidence of benefit for the patients or medical knowledge.
Furthermore, the costs and hassle of changing a patient's medication means most were likely to remain on the newer, more expensive drugs regardless. The rules are tighter in the United States than in Europe, where far fewer such trials are conducted, the study found.
Professor Gale said: "Since marketing can be guaranteed to expand in any direction that is not expressly forbidden, this type of study will continue unless tighter regulation is introduced. This should provide a much clearer definition of what constitutes a legitimate non-interventional study."
India, where more than 1,700 people are known to have died between 2005 and 2010 while participating in clinical trials for multinational drug companies, has seen one of the biggest rapid expansions in clinical trials since its regulatory system was relaxed in 2005.
The Independent's investigation last year raised serious questions about the ethical oversight and protection for patients in countries such as India. The country is one of the prime targets for companies doing post-marketing studies for diabetes drugs as with 40million sufferers it has more diabetics than any other country in the world.
In the third BMJ paper, a former researcher from a major drug company, said: "Some of the studies I worked on were not designed to determine the overall risk:... they were designed to support and disseminate a marketing message."
Life & Style blogs
Million pound investment to bring Liverpool homes back into use
Dozens of empty homes in two of Liverpool’s most deprived areas will be brought back into use thanks...
London renters are getting poorer and moving further out
Plus, do energy saving measures boost house prices?
-
The 10 Best Scotch Whiskies
-
The 10 Best new smartphones
-
Bollywood star, Shahrukh Khan, accused of choosing sex of baby
-
Uncooked curry leaves caused mass outbreak of salmonella in Newcastle, say health officials
-
Stripes set to be big for Dolce and Gabbana as fashion designers get 20 months in prison for tax evasion
- 1 Bankers could face jail after report urges the Government to introduce new criminal offence for reckless management
- 2 Breaking the Silence: In the reality of occupation, there are no Palestinian civilians – only potential terrorists
- 3 Richard Nieuwenhuizen death: Six teenagers and 50-year-old father convicted of manslaughter in shocking case of referee killed over a game of football
- 4 Exclusive: Newcastle's star talent-spotter on brink as Joe Kinnear sparks walkout
- 5 Vast methane 'plumes' seen in Arctic ocean as sea ice retreats
How will you make today delicious?
Tell us how you plan to make today delicious and you could win a £50 M&S gift card.
Win a Nook® Simple Touch eReader
Find out how Nook® is supporting the Evening Standard's Get Reading campaign - and your chance to win one.
Free reading festival for families
Follow The Standard's campaign to get London's children reading - and experience this unique event at Trafalgar Square on 13 July.
Enter the latest Independent competitions
Win anything from gadgets to five-star holidays on our competitions and offers page.
Business videos from commercial thought leaders
Watch the best in the business world give their insights into the world of business.
iJobs General
FX Options Front Office Java / C# Developer
£500 - £600 per day: Orgtel: FX Options Front Office Java / C# Developer - Ba...
Project Manager - Front Office - Regulatory IT
£600 - £700 per day: Orgtel: Project Manager - Front Office - Regulatory IT C...
Lighting Design Engineer
£33000 - £35000 Per Annum: The Green Recruitment Company: The Green Recruitmen...
Are you an Primary NQT looking for your first role in Essex?
£21000 - £22000 per annum: Randstad Education Chelmsford: NQTs required now fo...
Babies behind bars
Sonic youth: The high-pitched sound alarm
The art of living in small spaces
'Teaching bright children isn't rocket science'
Can technology lure us back to the high street?





Comments